⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
In a phase 3, double-blind, placebo-controlled trial (CLARITY-AD, NCT03887455), 1,795 patients with early Alzheimer's disease (MCI or mild dementia + amyloid-positive) received lecanemab 10 mg/kg IV biweekly or placebo for 18 months. The primary endpoint CDR-SB decreased by 0.45 points less in the lecanemab group (95% CI -0.67 to -0.23; P<0.001), representing 27% slowing of decline. Amyloid burden was reduced by 59.1 centiloids. ARIA-E occurred in 12.6%, infusion reactions in 26.4%. Funded by Eisai and Biogen.
Coeff. authors = avg(0.40, 0.70) = 0.55
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.55, 0.95) = 0.55← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.55
Final score = 42.4/52.8 × 0.55 × 100 = 44/100